Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard, Gregg J. Silverman
doi: https://doi.org/10.1101/2024.01.23.24301671

Article Information

doi 
https://doi.org/10.1101/2024.01.23.24301671
History 
  • January 24, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Ilya Kister, MD1,*,
  2. Ryan Curtin, BS2,
  3. Amanda L. Piquet, MD3,
  4. Tyler Borko, BA3,
  5. Jinglan Pei, PhD4,
  6. Barbara L Banbury, PhD5,
  7. Tamar E. Bacon, BA1,
  8. Angie Kim, BA1,
  9. Michael Tuen, BA6,
  10. Yogambigai Velmurugu, PhD2,
  11. Samantha Nyovanie, MPhil2,
  12. Sean Selva, BA3,
  13. Marie I. Samanovic, PhD6,
  14. Mark J. Mulligan, MD6,
  15. Yury Patskovsky, PhD2,
  16. Jessica Priest, PharmD4,
  17. Mark Cabatingan, PhD4,
  18. Ryan C. Winger, PhD4,
  19. Michelle Krogsgaard, PhD2,* and
  20. Gregg J. Silverman, MD7,*
  1. 1NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY
  2. 2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY
  3. 3Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO
  4. 4Genentech, Inc., South San Francisco, CA
  5. 5Adaptive Biotechnologies, Seattle, WA, USA
  6. 6NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, NY
  7. 7Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY
  1. ↵*Corresponding authors:
    Ilya Kister, Department of Neurology, New York University Grossman School of Medicine, 240 East 38th St, Thirteenth Floor, New York, NY 10016, (646) 501-7500, ilya.kister{at}nyulangone.org, Michelle Krogsgaard, PhD, Department of Pathology, New York University Grossman School of Medicine, Smilow Research Center, 522 First Avenue, 701C, New York, NY 10016, (212) 263-9266, michelle.krogsgaard{at}nyulangone.org, Gregg Silverman, MD, Department of Medicine, NYU Grossman School of Medicine, 435 E 30th Street, Room 517, New York, NY 10016, (212) 263-9440, gregg.silverman{at}nyulangone.org

  1. ↵* Contributed equally

Back to top
Posted January 24, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination
Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard, Gregg J. Silverman
medRxiv 2024.01.23.24301671; doi: https://doi.org/10.1101/2024.01.23.24301671
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area